Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease

AUTOR(ES)

Cohen, R D

FONTE

BMJ Group

RESUMO

The use of anti‐tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell‐mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti‐TNF agent, for Crohn's disease.

Documentos Relacionados

• Metastatic Crohn’s disease despite infliximab therapy
• Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone
• Long-term response rates to infliximab therapy for Crohn’s disease in an outpatient cohort
• Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease,
• Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease